Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (27 quarters reported)
$165M in Q4 2019 → $1.51B now. Hover for any quarter.
As reported for the quarter ended June 30, 2026. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Oruka Therapeutics Inc | 23.3% | Unchanged | 3,705,262 | $353M |
| DT Dianthus Therapeutics Inc | 16.3% | Unchanged | 2,537,191 | $247M |
| Damora Therapeutics Inc | 15.0% | Unchanged | 8,713,000 | $227M |
| Cogent Biosciences Inc | 14.1% | Unchanged | 5,503,418 | $213M |
| Jade Biosciences Inc | 6.7% | Unchanged | 4,553,494 | $101M |
| Enliven Therapeutics Inc | 6.2% | Unchanged | 1,855,644 | $94.2M |
| VT Viridian Therapeutics Inc | 6.2% | Added 30% | 5,090,928 | $93.5M |
| Zenas Biopharma Inc | 4.0% | Unchanged | 2,359,025 | $59.9M |
| Crescent Biopharma Inc. | 3.3% | Unchanged | 2,747,866 | $49.5M |
| Apogee Therapeutics Inc | 2.6% | Unchanged | 298,647 | $39.6M |
| Faeth Therapeutics Inc | 1.2% | New | 722,020 | $18.1M |
| Inhibikase Therapeutics Inc | 1.2% | Unchanged | 8,625,000 | $17.5M |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.
quarter ended June 30, 2026 · filed August 14, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Spyre Therapeutics Inc | Exited | −4,018,101 | −$203M | — |
| VT Viridian Therapeutics Inc | Added | +1,176,470 | +$21.6M | 6.2% |
| Faeth Therapeutics Inc | New | +722,020 | +$18.1M | 1.2% |
quarter ended March 31, 2026 · filed May 15, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Damora Therapeutics Inc | New | +8,713,000 | +$226M | 16.3% |
| Apogee Therapeutics Inc | Trimmed | −1,750,000 | −$147M | 1.8% |
| Cogent Biosciences Inc | Trimmed | −3,500,000 | −$135M | 15.3% |
| Nuvalent Inc | Exited | −727,563 | −$73.2M | — |
| Enliven Therapeutics Inc | Trimmed | −1,855,800 | −$72.7M | 5.3% |
| KP Kiniksa Pharmaceuticals Intl | Exited | −1,319,688 | −$54.4M | — |
| DT Dianthus Therapeutics Inc | Added | +400,000 | +$33.6M | 15.4% |
| Zenas Biopharma Inc | Added | +150,000 | +$2.93M | 3.3% |
quarter ended December 31, 2025 · filed February 17, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Axsome Therapeutics Inc | Exited | −815,176 | −$99M | — |
| SR Scholar Rock Hldg Corp | Exited | −1,824,031 | −$67.9M | — |
| Abivax Sa | Exited | −713,434 | −$60.6M | — |
| DT Dianthus Therapeutics Inc | Trimmed | −1,170,000 | −$48.2M | 6.7% |
| Astria Therapeutics Inc | Exited | −3,554,129 | −$25.9M | — |
| Jade Biosciences Inc | Added | +1,333,126 | +$20.6M | 5.3% |
| KP Kiniksa Pharmaceuticals Intl | Trimmed | −453,151 | −$18.7M | 4.1% |
| Crescent Biopharma Inc. | Added | +1,360,000 | +$16.1M | 2.5% |
| VT Viridian Therapeutics Inc | Added | +454,545 | +$14.1M | 9.3% |
| Zenas Biopharma Inc | Added | +316,219 | +$11.5M | 6.1% |
Showing the 10 largest of 11 changes.
quarter ended September 30, 2025 · filed November 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Abivax Sa | New | +713,434 | +$60.6M | 5.4% |
| Cogent Biosciences Inc | Added | +2,777,777 | +$39.9M | 11.6% |
| DT Dianthus Therapeutics Inc | Added | +600,000 | +$23.6M | 11.7% |
| Cytomx Therapeutics Inc | Exited | −3,896,582 | −$8.85M | — |
| Oruka Therapeutics Inc | Added | +333,340 | +$6.41M | 6.4% |
quarter ended June 30, 2025 · filed August 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Jade Biosciences Inc | New | +3,220,368 | +$32.2M | 4.2% |
| Crescent Biopharma Inc. | New | +1,387,866 | +$22.4M | 2.9% |
| KP Kiniksa Pharmaceuticals Intl | Added | +670,591 | +$18.6M | 6.4% |
| SR Scholar Rock Hldg Corp | Added | +450,000 | +$15.9M | 8.4% |
| Bicara Therapeutics Inc | Exited | −784,170 | −$10.2M | — |
| Enliven Therapeutics Inc | Added | +508,646 | +$10.2M | 9.6% |
| Cytomx Therapeutics Inc | New | +3,896,582 | +$8.85M | 1.1% |
| VT Viridian Therapeutics Inc | Added | +14,100 | +$197K | 6.3% |
| DT Dianthus Therapeutics Inc | Added | +6,500 | +$121K | 6.5% |
quarter ended March 31, 2025 · filed May 15, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Axsome Therapeutics Inc | Trimmed | −653,807 | −$76.3M | 14.7% |
| Nuvalent Inc | Trimmed | −590,101 | −$41.8M | 8.0% |
| Day One Biopharmaceuticals Inc | Exited | −3,103,448 | −$39.3M | — |
| KP Kiniksa Pharmaceuticals Intl | Trimmed | −1,092,093 | −$24.3M | 3.8% |
| Anaptysbio Inc | Exited | −1,816,466 | −$24.1M | — |
| SR Scholar Rock Hldg Corp | Trimmed | −588,922 | −$18.9M | 6.9% |
| Bicara Therapeutics Inc | Trimmed | −499,999 | −$6.51M | 1.6% |
quarter ended December 31, 2024 · filed February 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| SR Scholar Rock Hldg Corp | New | +1,962,953 | +$84.8M | 8.4% |
| Axsome Therapeutics Inc | Trimmed | −891,094 | −$75.4M | 12.4% |
| Nuvalent Inc | Trimmed | −369,400 | −$28.9M | 10.3% |
| Anaptysbio Inc | New | +1,816,466 | +$24.1M | 2.4% |
| KP Kiniksa Pharmaceuticals Intl | Trimmed | −1,010,500 | −$20M | 4.3% |
| Inhibikase Therapeutics Inc | New | +6,125,000 | +$19.9M | 2.0% |
| Oruka Therapeutics Inc | Added | +160,000 | +$3.1M | 6.5% |
| Bicycle Therapeutics PLC | Exited | −123,538 | −$2.8M | — |
quarter ended September 30, 2024 · filed November 14, 2024
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Oruka Therapeutics Inc | New | +3,211,922 | +$78.7M | 6.4% |
| Day One Biopharmaceuticals Inc | New | +3,103,448 | +$43.2M | 3.5% |
| VT Viridian Therapeutics Inc | Added | +1,600,000 | +$36.4M | 6.4% |
| Bicara Therapeutics Inc | New | +1,284,169 | +$32.7M | 2.7% |
| Protagonist Therapeutics Inc | Exited | −931,890 | −$32.3M | — |
| Zenas Biopharma Inc | New | +1,892,806 | +$32M | 2.6% |
| Nuvalent Inc | Trimmed | −237,562 | −$24.3M | 14.0% |
| Bicycle Therapeutics PLC | Trimmed | −945,661 | −$21.4M | 0.2% |
| Terns Pharmaceuticals Inc | Exited | −748,996 | −$5.1M | — |
| DT Dianthus Therapeutics Inc | Trimmed | −62,146 | −$1.7M | 6.0% |
Loading...
